Coconut oil – one of the most popular fats in the modern American lifestyle. Exploding from obscure product to true phenomenon, this tasty treat is also extremely controversial. At the same time that coconut oil saw a huge increase in American consumption, related products (like coconut water) also greatly expanded in popularity. For example, coconut water on its own is now a $300 million dollar per year industry. For a product that barely existed (in terms of sales) a decade ago – this is truly an overnight phenomenon.
But back to coconut oil. It has been called a “miracle cure”, a “cure for Alzheimer’s”, and almost everything in between. In 2015 alone, Americans spent over $220 million on coconut oil products. However, last year, the American Heart Association announced that coconut oil may not be all that it’s cracked up to be. Attracting headlines from all over the world, this report was seen as a public declaration that the coconut oil era may indeed be over. Aligning with this, were decreased sales of over 25% last year, compared with the record high sales of 2015 for coconut oil.
But what does the scientific evidence say? The main scientific claim against coconut oil (according to the AHA, and others) – is that it simply has too much saturated fat. But we in the Paleo community know that saturated fat is not a problem. If we look at the scientific data for coconut oil, we see a myriad of studies that show its ingredients (like medium- chain triglycerides) actually show vast effectiveness for weight loss, as well as an increase in metabolism.
In fact, some studies have even shown that less calories are likely to be consumed, overall, when eating coconut oil on a regular basis. This is likely due to the various hormonal, cellular, and other effects that coconut oil (and its compounds) have on the body. Other scientific studies have shown that coconut oil actually raises HDL cholesterol (the “good” cholesterol), and decreases waist size, as well as overall body mass.
Other research shows that coconut oil has positive impacts on visceral adiposity specifically, as well as up to a 30% decrease in C-reactive protein (CRP) – which is one of the biggest indicators of overall inflammation in the body. A 30% decrease in C-reactive protein is by far one of the strongest pieces of scientific evidence that backs up the claim that coconut oil is a ‘miracle cure’ – but the benefits do not stop there.
Other scientific studies have shown that some compounds within coconut oil may help with preventing the buildup of plaques and peptides, which lead to Alzheimer’s disease. Specifically, researchers have looked at preventing the buildup of beta-amyloid plaque, and how regular consumption of coconut oil can help with this process. Research has shown that coconut oil indeed does protect neurons from beta-amyloid buildup, specifically by improving cellular signaling in critical cell pathways. Coconut oil also contains another beneficial compound called monolaurin, which is formed when coconut oil is broken down inside the body. This compound is part of how coconut oil has such great anti-viral and anti-inflammatory effects within the body.
Coconut oil also has vast benefits for those undertaking a keto approach to nutrition, because of its high concentration of brain-boosting compounds, like lauric acid (a medium- chain fat). Biochemically, compounds like this are extremely important for ketosis, as they go from your small intestine, right to your liver, and are broken down for rapid energy. This biochemical difference is a large reason why the medium- chain triglycerides found in coconut oil are greatly beneficial for your brain, as well as for a ketogenic approach to eating. It should also be noted that these types of triglycerides are almost entirely found solely in coconut oil – not amongst other cooking fats.
So, is this simply a case of mistaken identity, and poorly reported (and understood) science? Perhaps, but the decline in coconut oil sales may also have to do with outside trends and marketing. As soon as coconut oil started to take off in popularity, food manufacturers saw a huge opportunity. They ramped up production and marketing efforts with other “healthy” oils, so suddenly consumers were buying grass-fed butter, extra virgin olive oil, avocado oil – and many other products. Many times, consumers replaced coconut oil with these products – leading to a decline in sales numbers for coconut oil itself.
Of course, as a personal trainer and nutritionist, I just want consumers to use healthier oils, and to avoid canola oil (and other inflammatory choices). But the negative backlash against coconut oil troubles me, largely because it seems to still be a re-tread of a war that was already lost – the war against fat, in general. For decades, largely due to Ancel Keys, we were told that all fat is bad for us, and the only way to be healthy was to follow a low- fat, high- carb diet. Of course, this fallacy led us to the highest level of obesity the world has ever seen, and scientists finally realized that carbs and sugar were the real demons.
Nonetheless, the backlash against coconut oil still somehow persists. There is quite a bit of money in unhealthy food and beverage promotion, and as large corporations like Coca-Cola and Pepsi panic over increasingly falling sales, they tend to ramp up attacks on these healthier choices. The science is clear, however. Soda is by far the biggest contributor to obesity (especially in children) and has very well-documented negative effects throughout our body.
While nothing is truly a ‘miracle cure’ and must work within the context of an overall healthy eating approach, coconut oil and its compounds do indeed have vast benefits for weight loss, neuronal functioning, and an increased metabolism. It also has a very high smokeburn point, meaning it can be used to cook just about anything, without breaking down into more inflammatory compounds. Coconut oil ultimately may not be a miracle cure – but it is still one of the healthiest oils to consume, as well as to cook and bake with. It fits into a Paleo Diet perfectly – and is a great addition to a diet filled with real, whole foods. Enjoy responsibly!
- Abeywardena M. Dietary fats, carbohydrates and vascular disease: Sri Lankan perspectives. Atherosclerosis. 2003;171:157–161.
- Acheson K. J., Gremaud G., Meirim I., Montigon F., Krebs Y., Fay L. B., et al. (2004). Metabolic effects of caffeine in humans: lipid oxidation or futile cycling? Am. J. Clin. Nutr. 79 40–46.
- Adam P. A., Raiha N., Rahiala E. L., Kekomaki M. (1975). Oxidation of glucose and D-B-OH-butyrate by the early human fetal brain. Acta Paediatr. Scand. 64 17–24.
- Bach A, Babayan V. Medium-chain triglycerides: an update. Am J Clin Nutr. 1982;36:950–962.
- Baker L. D., Cross D. J., Minoshima S., Belongia D., Watson G. S., Craft S. (2011). Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 68 51–57.
- Balasse E. O., Fery F. (1989). Ketone body production and disposal: effects of fasting, diabetes, and exercise. Diabetes Metab. Rev. 5 247–270.
- Balasse E. O., Fery F., Neef M. A. (1978). Changes induced by exercise in rates of turnover and oxidation of ketone bodies in fasting man. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 44 5–11.
- Beegom R, Singh RB. Association of higher saturated fat intake with higher risk of hypertension in an urban population of Trivandrum in South India. Int J Cardiol. 1997;58:63–70.
- Bekesi A., Williamson D. H. (1990). An explanation for ketogenesis by the intestine of the suckling rat: the presence of an active hydroxymethylglutaryl-coenzyme A pathway. Biol. Neonate 58 160–165.
- Benson D. F., Kuhl D. E., Hawkins R. A., Phelps M. E., Cummings J. L., Tsai S. Y. (1983). The fluorodeoxyglucose 18F scan in Alzheimer’s disease and multi-infarct dementia. Arch. Neurol. 40 711–714.
- Bickerton A. S., Roberts R., Fielding B. A., Tornqvist H., Blaak E. E., Wagenmakers A. J., et al. (2008). Adipose tissue fatty acid metabolism in insulin-resistant men. Diabetologia 51 1466–1474.
- Blass J. P. (2008). A new approach to treating Alzheimer’s disease. Ann. N. Y. Acad. Sci. 1147 122–128.
- Bougneres P. F., Lemmel C., Ferre P., Bier D. M. (1986). Ketone body transport in the human neonate and infant. J. Clin. Invest. 77 42–48.
- Bowen D. M., White P., Spillane J. A., Goodhardt M. J., Curzon G., Iwangoff P., et al. (1979). Accelerated ageing or selective neuronal loss as an important cause of dementia? Lancet 1 11–14.
- Breckenridge W. C., Kuksis A. (1967). Molecular weight distributions of milk fat triglycerides from seven species. J. Lipid Res. 8 473–478.
- Brunengraber H., Roe C. R. (2006). Anaplerotic molecules: current and future. J. Inherit. Metab. Dis. 29 327–331.
- Burns C. M., Chen K., Kaszniak A. W., Lee W., Alexander G. E., Bandy D., et al. (2013). Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology 80 1557–1564.
- Cahill G. F., Jr. (2006). Fuel metabolism in starvation. Annu. Rev. Nutr. 26 1–22.
- Castellano C. A., Baillargeon J. P., Nugent S., Tremblay S., Fortier M., Imbeault H., et al. (2015a). Regional brain glucose hypometabolism in young women with polycystic ovary syndrom: possible link to mild insulin resistance. PLoS ONE 10:e0144116
- Castellano C. A., Nugent S., Paquet N., Tremblay S., Bocti C., Lacombe G., et al. (2015b). Lower brain 18F-Fluorodeoxyglucose uptake but normal 11C-Acetoacetate metabolism in mild Alzheimer’s Disease dementia. J. Alzheimers Dis. 43 1343–1353.
- Courchesne-Loyer A., St-Pierre V., Hennebelle M., Castellano C. A., Fortier M., Tessier D., et al. (2015). Ketogenic response to cotreatment with bezafibrate and medium chain triacylglycerols in healthy humans. Nutrition 31 1255–1259.
- Craft S. (2012). Alzheimer disease: insulin resistance and AD–extending the translational path. Nat. Rev. Neurol. 8 360–362.
- Cunnane S. C., Courchesne-Loyer A., St-Pierre V., Vandenberghe C., Pierotti T., Fortier M., et al. (2016). Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer’s disease. Ann. N. Y. Acad. Sci. 1367 12–20.
- De Gaetano A., Castagneto M., Mingrone G., Gangeri G., Sganga G., Tataranni P. A., et al. (1994). Kinetics of medium-chain triglycerides and free fatty acids in healthy volunteers and surgically stressed patients. JPEN J. Parenter. Enteral. Nutr. 18 134–140.
- Drenick E. J., Alvarez L. C., Tamasi G. C., Brickman A. S. (1972). Resistance to symptomatic insulin reactions after fasting. J. Clin. Invest. 51 2757–2762.
- Ebert D., Haller R. G., Walton M. E. (2003). Energy contribution of octanoate to intact rat brain metabolism measured by 13C nuclear magnetic resonance spectroscopy. J. Neurosci. 23 5928–5935.
- Eyres L. Analysis of edible oils and fats. Chem New Zeal. 1979;43:237–239.
- Feranil AB, Duazo PL, Kuzawa CW, et al. Coconut oil is associated with a beneficial lipid profile in pre-menopausal women in the Philippines. Asia Pac J Clin Nutr. 2011;20:190–195.
- Flatt J. P. (1972). On the maximal possible rate of ketogenesis. Diabetes Metab. Res. Rev. 21 50–53.
- Foster RH, Wilson N. Review of the evidence for the potential impact and feasibility of substituting saturated fat in the New Zealand diet. Aust N Z J Public Health. 2013;37:329–336.
- Freemantle E., Vandal M., Tremblay Mercier J., Plourde M., Poirier J., Cunnane S. C. (2009). Metabolic response to a ketogenic breakfast in the healthy elderly. J. Nutr. Health Aging 13 293–298.
- Fulop T., Dupuis G., Baehl S., Le Page A., Bourgade K., Frost E., et al. (2015). From inflamm-aging to immune-paralysis: a slippery slope during aging for immune-adaptation. Biogerontology 17 147–157.
- Fulop T., Lacombe G., Cunnane S., Le Page A., Dupuis G., Frost E. H., et al. (2013). Elusive Alzheimer’s disease: can immune signatures help our understanding of this challenging disease? Part 2: new immune paradigm. Discov. Med. 15 33–42.
- Garber A. J., Menzel P. H., Boden G., Owen O. E. (1974). Hepatic ketogenesis and gluconeogenesis in humans. J. Clin. Invest. 54 981–989.
- Halestrap A. P., Price N. T. (1999). The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem. J. 343(Pt 2), 281–299.
- Hall S. E., Wastney M. E., Bolton T. M., Braaten J. T., Berman M. (1984). Ketone body kinetics in humans: the effects of insulin-dependent diabetes, obesity, and starvation. J. Lipid Res. 25 1184–1194.
- Hasselbalch S. G., Knudsen G. M., Jakobsen J., Hageman L. P., Holm S., Paulson O. B. (1995). Blood-brain barrier permeability of glucose and ketone bodies during short-term starvation in humans. Am. J. Physiol. 268(6 Pt 1), E1161–E1166.
- Henderson S. T. (2008). Ketone bodies as a therapeutic for Alzheimer’s disease. Neurotherapeutics 5 470–480.
- Hennebelle M., Courchesne-Loyer A., St-Pierre V., Vandenberghe C., Castellano C. A., Fortier M., et al. (2016). Preliminary evaluation of a differential effect of an alpha-linolenate-rich supplement on ketogenesis and plasma omega-3 fatty acids in young compared to older adults. Nutrition 16 30040–30045.
- Herholz K., Salmon E., Perani D., Baron J. C., Holthoff V., Frolich L., et al. (2002). Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17 302–316.
- Hertz L., Chen Y., Waagepetersen H. S. (2015). Effects of ketone bodies in Alzheimer’s disease in relation to neural hypometabolism, beta-amyloid toxicity, and astrocyte function. J. Neurochem. 134 7–20.
- Hilditch T. P., Meara M. L. (1944). Human-milk fat: 1. Component fatty acids. Biochem. J. 38 29–34.
- Huttenlocher P. R. (1976). Ketonemia and seizures: metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy. Pediatr. Res. 10 536–540.
- Insull W., Jr., Ahrens E. H., Jr. (1959). The fatty acids of human milk from mothers on diets taken ad libitum. Biochem. J. 72 27–33.
- Ishibashi K., Onishi A., Fujiwara Y., Ishiwata K., Ishii K. (2015). Relationship between Alzheimer disease-like pattern of 18F-FDG and fasting plasma glucose levels in cognitively normal volunteers. J. Nucl. Med. 56 229–233.
- Iwangoff P., Armbruster R., Enz A., Meier-Ruge W. (1980). Glycolytic enzymes from human autoptic brain cortex: normal aged and demented cases. Mech. Ageing Dev. 14 203–209.
- Kalpouzos G., Chetelat G., Baron J. C., Landeau B., Mevel K., Godeau C., et al. (2009). Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol. Aging 30 112–124.
- Kashiwaya Y., Takeshima T., Mori N., Nakashima K., Clarke K., Veech R. L. (2000). D-beta-hydroxybutyrate protects neurons in models of Alzheimer’s and Parkinson’s disease. Proc. Natl. Acad. Sci. U.S.A. 97 5440–5444.
- Kuge Y., Yajima K., Kawashima H., Yamazaki H., Hashimoto N., Miyake Y. (1995). Brain uptake and metabolism of [1-11C]octanoate in rats: pharmacokinetic basis for its application as a radiopharmaceutical for studying brain fatty acid metabolism. Ann. Nucl. Med. 9 137–142.
- Kumar PD. The role of coconut and coconut oil in coronary heart disease in Kerala, South India. Trop Doc. 1997;27:215–217.
- Lying-Tunell U., Lindblad B. S., Malmlund H. O., Persson B. (1981). Cerebral blood flow and metabolic rate of oxygen, glucose, lactate, pyruvate, ketone bodies and amino acids. Acta Neurol. Scand. 63 337–350.
- Maalouf M., Rho J. M., Mattson M. P. (2009). The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res. Rev. 59 293–315.
- Mamelak M. (2012). Sporadic Alzheimer’s disease: the starving brain. J. Alzheimers Dis. 31 459–474.
- Marina A, Che-Man Y, Nazimah S, et al. Chemical properties of virgin coconut oil. J Am Oil Chem Soc. 2009;86:301–307.
- Marten B, Pfeuffer M, Schrezenmeir J. Medium-chain triglycerides. Int Dairy J. 2006;16:1374–1382.
- Matsuzaki T., Sasaki K., Tanizaki Y., Hata J., Fujimi K., Matsui Y., et al. (2010). Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 75 764–770.
- Mendis S, Kumarasunderam R. The effect of daily consumption of coconut fat and soya-bean fat on plasma lipids and lipoproteins of young normolipidaemic men. Br J Nutr. 1990;63:547–552.
- Mendis S, Samarajeewa U, Thattil RO. Coconut fat and serum lipoproteins: effects of partial replacement with unsaturated fats. Br J Nutr. 2001;85:583–589.
- Mitchell G. A., Kassovska-Bratinova S., Boukaftane Y., Robert M. F., Wang S. P., Ashmarina L., et al. (1995). Medical aspects of ketone body metabolism. Clin. Invest. Med. 18 193–216.
- Njelekela M, Kuga S, Nara Y, et al. Prevalence of obesity and dyslipidemia in middle-aged men and women in Tanzania, Africa: relationship with resting energy expenditure and dietary factors. J Nutr Sci Vitaminol. 2002;48:352–358.
- Njelekela M, Sato T, Nara Y, et al. Nutritional variation and cardiovascular risk factors in Tanzania – rural-urban difference. S Afr Med J. 2003;93:295–299.
- Nugent S., Tremblay S., Chen K. W., Ayutyanont N., Roontiva A., Castellano C. A., et al. (2014b). Brain glucose and acetoacetate metabolism: a comparison of young and older adults. Neurobiol. Aging 35 1386–1395.
- Owen O. E., Reichard G. A., Jr., Markus H., Boden G., Mozzoli M. A., Shuman C. R. (1973). Rapid intravenous sodium acetoacetate infusion in man. Metabolic and kinetic responses. J. Clin. Invest. 52 2606–2616.
- Page K. A., Williamson A., Yu N., McNay E. C., Dzuira J., McCrimmon R. J., et al. (2009). Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia. Diabetes 58 1237–1244.
- Pi-Sunyer F. X., Hashim S. A., Van Itallie T. B. (1969). Insulin and ketone responses to ingestion of medium and long-chain triglycerides in man. Diabetes Metab. Res. Rev. 18 96–100.
- Plecko B., Stoeckler-Ipsiroglu S., Schober E., Harrer G., Mlynarik V., Gruber S., et al. (2002). Oral beta-hydroxybutyrate supplementation in two patients with hyperinsulinemic hypoglycemia: monitoring of beta-hydroxybutyrate levels in blood and cerebrospinal fluid, and in the brain by in vivo magnetic resonance spectroscopy. Pediatr. Res. 52 301–306.
- Reger M. A., Henderson S. T., Hale C., Cholerton B., Baker L. D., Watson G. S., et al. (2004). Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol. Aging 25 311–314.
- Reichard G. A., Jr., Owen O. E., Haff A. C., Paul P., Bortz W. M. (1974). Ketone-body production and oxidation in fasting obese humans. J. Clin. Invest. 53 508–515.
- Reiman E. M., Chen K., Alexander G. E., Caselli R. J., Bandy D., Osborne D., et al. (2004). Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc. Natl. Acad. Sci. U.S.A. 101 284–289.
- Reiser R, Probstfield JL, Silvers A, et al. Plasma lipid and lipoprotein response of humans to beef fat, coconut oil and safflower oil. Am J Clin Nutr. 1985;42:190–197.
- Robinson A. M., Williamson D. H. (1980). Physiological roles of ketone bodies as substrates and signals in mammalian tissues. Physiol. Rev. 60 143–187.
- Sabitha P, Vaidyanathan K, Vasudevan DM, et al. Comparison of lipid profile and antioxidant enzymes among south Indian men consuming coconut oil and sunflower oil. Indian J Clin Biochem. 2009;24:76–81.
- Sarda P., Lepage G., Roy C. C., Chessex P. (1987). Storage of medium-chain triglycerides in adipose tissue of orally fed infants. Am. J. Clin. Nutr. 45 399–405.
- Scholl M., Almkvist O., Bogdanovic N., Wall A., Langstrom B., Viitanen M., et al. (2011). Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers. J. Alzheimers Dis. 24 495–506.
- Schrijvers E. M., Witteman J. C., Sijbrands E. J., Hofman A., Koudstaal P. J., Breteler M. M. (2010). Insulin metabolism and the risk of Alzheimer disease: the rotterdam study. Neurology 75 1982–1987.
- Seaton T. B., Welle S. L., Warenko M. K., Campbell R. G. (1986). Thermic effect of medium-chain and long-chain triglycerides in man. Am. J. Clin. Nutr. 44 630–634.
- Settergren G., Lindblad B. S., Persson B. (1976). Cerebral blood flow and exchange of oxygen, glucose, ketone bodies, lactate, pyruvate and amino acids in infants. Acta Paediatr. Scand. 65 343–353.
- Simpson I. A., Carruthers A., Vannucci S. J. (2007). Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J. Cereb. Blood Flow Metab. 27 1766–1791.
- Sivakumaran S, Huffman L. The Concise New Zealand Food Composition Tables. 11th ed. Palmerston North, New Zealand: New Zealand Institute for Plant and Food Research Limited and Ministry of Health New Zealand; 2014.
- Sorbi S., Bird E. D., Blass J. P. (1983). Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann. Neurol. 13 72–78.
- Srivastava S, Singh M, George J, et al. Genotoxic and carcinogenic risks associated with the dietary consumption of repeatedly heated coconut oil. Br J Nutr. 2010;104:1343–1352.
- St-Onge M. P., Jones P. J. (2002). Physiological effects of medium-chain triglycerides: potential agents in the prevention of obesity. J. Nutr. 132 329–332.
- Swift LL, Hill JO, Peters JC, et al. Medium-chain fatty acids: evidence for incorporation into chylomicron triglycerides in humans. Am J Clin Nutr. 1990;52:834–836.
- Timmermann F. Oils and Fats in the Nineties. Lystrup, Denmark: International Food Science Centre; 1992.
- Traul K. A., Driedger A., Ingle D. L., Nakhasi D. (2000). Review of the toxicologic properties of medium-chain triglycerides. Food Chem. Toxicol. 38 79–98.
- Tremblay S., Ouellet R., Rodrigue S., Langlois R., Benard F., Cunnane S. C. (2007). Automated synthesis of 11C-acetoacetic acid, a key alternate brain fuel to glucose. Appl. Radiat. Isot. 65 934–940.
- Tremblay-Mercier J., Tessier D., Plourde M., Fortier M., Lorrain D., Cunnane S. C. (2010). Bezafibrate mildly stimulates ketogenesis and fatty acid metabolism in hypertriglyceridemic subjects. J. Pharmacol. Exp. Ther. 334 341–346.
- Trinidad TP, Loyola AS, Mallillin AC, et al. The cholesterol-lowering effect of coconut flakes in humans with moderately raised serum cholesterol. J Med Food. 2004;7:136–140.
- Voon PT, Ng TK, Lee VK, et al. Diets high in palmitic acid (16:0), lauric and myristic acids (12:0 + 14:0), or oleic acid (18:1) do not alter postprandial or fasting plasma homocysteine and inflammatory markers in healthy Malaysian adults. Am J Clin Nutr. 2011;94:1451–1457.
- Voon PT, Ng TKW, Lee VKM, et al. Virgin olive oil, palm olein and coconut oil diets do not raise cell adhesion molecules and thrombogenicity indices in healthy Malaysian adults. Eur J Clin Nutr. 2015;69:712–716.
- Vossel K. A., Beagle A. J., Rabinovici G. D., Shu H., Lee S. E., Naasan G., et al. (2013). Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 70 1158–1166.
- Wilkins H. M., Koppel S., Carl S. M., Ramanujan S., Weidling I., Michaelis M. L., et al. (2016). Oxaloacetate enhances neuronal cell bioenergetic fluxes and infrastructure. J. Neurochem. 137 76–87.
- Williams M, Tamai K, Hincenbergs T, et al. Hydrogenated coconut oil and tissue fatty acids in EFA-depleted and EFA-supplemented rats. J Nutr. 1972;102:847–856.
- Yao J., Irwin R. W., Zhao L., Nilsen J., Hamilton R. T., Brinton R. D. (2009). Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 106 14670–14675.
- Yin J. X., Maalouf M., Han P., Zhao M., Gao M., Dharshaun T., et al. (2016). Ketones block amyloid entry and improve cognition in an Alzheimer’s model. Neurobiol. Aging 39 25–37.
- Yong JW, Ge L, Ng YF, et al. The chemical composition and biological properties of coconut (Cocos nucifera L.) water. Molecules. 2009;14:5144–5164.
- Zilberter M., Ivanov A., Ziyatdinova S., Mukhtarov M., Malkov A., Alpar A., et al. (2013). Dietary energy substrates reverse early neuronal hyperactivity in a mouse model of Alzheimer’s disease. J. Neurochem. 125 157–171.